ACC.26 Scientific Sessions 2026
Updated US cholesterol guideline advises on PCSK9 inhibitor use
The updated guidance for the management of dyslipidaemias, issued by the American College of Cardiology (ACC), the American Heart Association (AHA) and nine other leading medical associations, includes new advice on the use of PCSK9 inhibitors for lowering lipid levels. The guidelines, which update and…
read more »
VESALIUS-CV: Evolocumab reduces risk of MACE in patients with diabetes
Treatment with evolocumab cut the risk of major adverse cardiac events (MACE) by nearly one-third in patients who did not have significant atherosclerosis but had diabetes, according to a new study. The subgroup analysis of 3,655 patients from the VESALIUS-CV trial found that the PSCK9…
read more »
CORALreef AddOn Trial: Enlicitide an ‘important add-on’ for statin-treated ASCVD patients
The oral PCSK9 inhibitor enlicitide decanoate was more effective than other oral non-statin therapies in statin-treated adults with a history of atherosclerotic cardiovascular disease (ASCVD) or at major risk of a first event, suggest new results. In these patients, treatment with enlicitide compared with bempedoic…
read more »
Lerodalcibep safe and efficacious in the longer term
The third-generation PCSK9 inhibitor lerodalcibep was effective and well-tolerated in patients with cardiovascular disease, according to an open-label extension trial. The results were given in a poster presentation by David Kallend and colleagues at LIB Therapeutics in Cincinnati, Ohio, at the American College of Cardiology’s…
read more »
